(NasdaqGM:KYMR), Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025 Initiated KT-621 BROADEN2 Phase 2b trial in AD KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 KT-579 (IRF5) IND-enabling studies completed, with Phase 1 clinical […]
(NasdaqGM:MAZE), SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in four upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference; fireside chat on Tuesday, November
(NASDAQ:BEAM), Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026 Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease Accepted for Presentation at American Society of Hematology (ASH)
The bipartisan group of state legislators and executive officers will focus on developing responsible AI policies while advancing AI-powered economic growth opportunities across the heartland Today, Heartland Forward announced the launch of the Heartland AI Caucus, a bipartisan group of state leaders committed to creating and accelerating smart AI policy and actionable outcomes to advance
(NASDAQ:HOWL), – Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – – Update on Phase 1b/2 clinical trial of WTX-330 and potential further development plan is expected to
(TSX:SJ), MONTREAL, Nov. 04, 2025 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX:SJ). Open to: Investors, analysts and all interested parties Date: Wednesday November 5, 2025 Time: 10:00 AM Eastern Standard Time (EST) Live Webcast: https://meetings.lumiconnect.com/400-700-172-835 Call: (+1) 800 990 2777 THE PRESS RELEASE WILL BE PUBLISHED BEFORE MARKET OPENS THE DAY OF THE CONFERENCE CALL THROUGH
(NASDAQ:MDGL), Third-quarter 2025 Rezdiffra(TM) (resmetirom) net sales of $287.3 million As of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash,
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors GlobeNewswire November 04, 2025 Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million
(NasdaqGM:BGL),(NasdaqGM:BGLWW), NEW YORK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) — Blue Gold Limited (Nasdaq: BGL) (“Blue Gold” or the “Company”), a next-generation gold development and technology company, today announced the appointment of Nathan Dionne as Chief Technology Officer (CTO), effective immediately. As CTO, Mr. Dionne will lead the delivery of the Company's digital strategy, overseeing
(NASDAQ:AMPG),(NASDAQ:AMPGW), HAUPPAUGE, N.Y., Nov. 04, 2025 (GLOBE NEWSWIRE) — AmpliTech Group, Inc (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private ORAN 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly,